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Background: The optimal course of clinical follow-up after a diagnosis of breast papillary lesion on a core needle
biopsy (CNB) remains elusive. In particular, no reports in literature have addressed this question in African-American
population. We describe our experience with breast papillary lesions in a primarily African-American population.
Methods: A search of our database for breast papillary lesions diagnosed on CNB between September 2002 and
September 2012 was conducted. Cases were categorized into benign, atypical, and malignant. CK5/6 and CK903
stains were performed when necessary.
Results: A total of 64 breast papillary lesions were diagnosed on CNB, including 55 (86%) benign papillary lesions,
6 (9%) atypical lesions, and 3 (5%) intraductal papillary carcinomas. Of these 64 patients, 29 patients (25 African-
Americans, 3 Hispanics, 1 Asian American) underwent lumpectomy within 6 months after CNB. Pathology of the
lumpectomy showed: five of the 25 (20%) benign papillary lesions on needle biopsy were upgraded to intraductal
or invasive papillary carcinoma; 2 of the 3 atypical papillary lesion cases on core biopsy were upgraded (67%), one
into intraductal papillary carcinoma, the other invasive papillary carcinoma; the only case of malignant papillary
lesion on CNB remained as intraductal papillary carcinoma on lumpectomy. The rate of upgrade in lumpectomy/
mastectomy was 25%. CK5/6 and CK903 immunostains were performed on all seven core needle biopsies that were
later upgraded.
Conclusions: In our predominantly African-American urban population, 25% of benign or atypical papillary lesions
diagnosed on CNB was upgraded in the final excisional examination. Early excision of all papillary lesions diagnosed
on CNB may be justified in this patient population.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/7950117821177201
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In current medical practice, most institutions recommend
surgical excision for atypical and malignant papillary
breast lesions diagnosed by ultrasound-guided core needle
biopsy (CNB). However, both surgical excision and serial
radiographic follow-up have been recommended by some
authors as appropriate management for benign papillary
lesions diagnosed by CNB [1-3]. A major argument for* Correspondence: he.wang@tuhs.temple.edu
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unless otherwise stated.surgical excision of nonmalignant papillary lesion diag-
nosed by CNB is an unacceptable upgrading rate after
excisional specimen evaluation, ranging from 0% to 29%
[4,5]. Several clinical and radiological variables, includ-
ing patient’s age, lesion size, BI-RADS category, and
microcalcification, have been examined regarding their
predicting value for pathological upgrading in later exci-
sional specimen [5,6].
Papillary lesions of the breast develop as tufts of epithe-
lium with fibrovascular cores that form branching papillae
and protrude into ductal lumen. They may present as
single or multiple lesions, broad-based or pedunculated.td. This is an Open Access article distributed under the terms of the Creative
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to malignant, including papilloma, papilloma with atypical
ductal hyperplasia, papillary carcinoma in situ, microinva-
sive papillary carcinoma and invasive papillary carcinoma.
Intraductal papilloma is the most common papillary lesion
of the breast, accounting for about 5% of benign mam-
mary disease. CNB is a well-established diagnostic ap-
proach for breast diseases, including papillary lesions. The
diagnostic accuracy of CNB depends on characteristics of
the lesions, experience of the radiologists and pathologists,
the number of the core specimens. Because the patho-
logical nature of a papillary lesion can vary significantly
even within a single lesion, insufficient sampling by CNB
has long been suspected as a contributing factor for un-
derestimation the severity of the lesion. Actually the re-
ported rates of underestimation in literature vary greatly
[7], directly responsible for the lack of consensus for clin-
ical management of nonmalignant papillary breast lesions.
Patient selection, including patient ethnicity, is a poten-
tial contributing factor for the reported variability of CNB
dignosis upgrading rates. In current study, we retrospect-
ively reviewed our experience with US-CNB in evaluating
breast papillary lesions over the past 10 years at a large
urban medical center in a primarily African American
population. Our results indicate a large percentage (25%)
of benign or atypical papillary lesions diagnosed on US-




Between September 2002 and September 2012, all pa-
tients underwent US-CNB of breast lesion in our med-
ical center with diagnosis of papillary lesion (papilloma,
papillomatosis, papilloma with atypical ductal hyperpla-
sia, papillary carcinoma in situ, and invasive papillary
carcinoma) were enrolled in this study. The primary in-
dication for US-CNB was the sampling and diagnosis of
breast nodule/mass detected by palpitation, ultrasound
or mammography. All patients with core biopsy were
followed for their further clinical management including
surgical procedure and radiological examination. This
study protocol was reviewed and approved by Newark
Beth Israel Medical Center: Institutional Review Board,
Institutional Ethics Committee.
Biopsy procedure
Breast US imaging, using both grayscale and color and
power Doppler US, was performed using high-resolution
scanners with high-frequency linear-array 10–14-MHz
transducers: 15L8W broadband transducer on Acuson,
Sequoia (Siemens Medical Solutions, Mountain View, CA),
or PLT1204AX matrix transducer on Aplio 80 (Toshiba
Medical Systems, Tokyo, Japan). The lesions were firstimaged with gray-scale US and then color Doppler US
was performed. 14-G and 18-G US-guided core biopsy
needles with a spring-loaded core biopsy device (Bard
Magnum; Bard Urological, Covington, GA) were used
in this study. Two to five core samples per lesion were
biopsied.
The US-guided vacuum-assisted biopsies (VABs) were
performed using a 10-G handheld VAB system (Vacora;
Bard Urological).
Mammography was performed in mediolateral and cra-
niocaudal imaging planes using film-screen mammo-
graphic equipment (M-IV mammographic unit; Hologic,
Bedford, MA). Additional mammographic projections were
performed as needed. The stereotactic guided core biopsies
were performed on a digital stereotactic table (LoRad
DSM; Hologic) using an 11-G Mammotone directional
VAB device (Ethicon Endo-Surgery, Cincinnati, OH).
All static and color Doppler images were stored on the
Picture Archiving and Communication System of our
medical center.
Final diagnosis
The recorded pathology results from the percutaneous
breast US-CNB and surgical excisional specimens were
included for the study and all pathology cases were
reviewed by 2 experienced pathologists.
The papillary lesions were categorized based on the core
biopsy result into three groups: benign, atypical or ma-
lignant. The benign category included the diagnoses of
benign papillary lesion, intraductal papilloma, sclerotic
intraductal papilloma, intraductal papilloma with florid
epithelial hyperplasia without atypia, papillomatosis, and
papillary hyperplasia. The atypical category included the
diagnoses of papilloma with atypical ductal hyperplasia,
papilloma with atypia, atypical papilloma, The malignant
category included malignant papillary lesion, papillary
ductal carcinoma in situ, intraductal papillary carcinoma,
microinvasive and invasive papillary carcinoma. For each
papillary lesion, the patient’s medical records were re-
viewed to identify whether surgery was performed. For
surgically excised lesions, the final surgical pathology (gold
standard in this study) was classified into benign, atypical
or malignant categories and compared with the initial
CNB result. Concordance or discordance between the two
results was documented. An upgraded lesion was defined
as a lesion that was benign (with/without atypia) on CNB
but showed (in situ or invasive) malignancy in the exci-
sion. It was assumed that the lesions were fully removed
at the time of surgery and follow-up imaging was therefore
not documented for these lesions.
Immunohistochemistry
Immunostains were performed following the protocols set
up by manufacturer (Leica Microsystem, Buffalo Grove,
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Bond, Newcastle, UK).
Statistical methods
Descriptive statistics were calculated for all variables, in-
cluding means, standard deviations, and proportions. A
t-test was used to characterize the relationship between
quantitative variables, and the Fisher exact test was used
to characterize the relationship between categorical vari-
ables. Throughout all analysis, 95% confidence intervals
were calculated for all parameters.
Results and discussion
Patient demographics
Over the 10 years of our review period, a total of 64 pa-
tients were diagnosed to have breast papillary lesion by
CNB. Eighty percent (51 patients) of these patients were
African-American and the mean age of the patients is
54 years old. The patients’ mean age and follow-up sta-
tus in the benign, atypical and malignant categories were
listed in Table 1.
Cases with surgical follow-up
Of the twenty-nine CNB patients who were managed by
surgical excision within six months after CNB diagnosis,
25 were African-American, 3 Hispanic and 1 Asian
American.
Pathology of the lumpectomy showed: five of the 25
(20%) benign papillary lesions on needle biopsy were
upgraded to intraductal or invasive papillary carcinoma;
2 of the 3 atypical papillary lesion cases on core biopsy
were upgraded (67%), one into intraductal papillary car-
cinoma, the other invasive papillary carcinoma; the only
case of malignant papillary lesion on core needle biopsy
remained as intraductal papillary carcinoma on lumpec-
tomy (Table 2, Figure 1A – F).
The average age of the patients who were upgraded by
surgical excision was 64.6 years; this was significantly
higher than that of the non-upgraded patients (47.7 years
old, p = 0.017). Differences between other variables, in-
cluding lesional size, distance from nipple, presence of
microcalcifications, and BI-RADS grade, did not reach
statistical significance (Table 3).
CK5/6 and CK903 immunostains were performed on
the CNBs of our No. 7 patient (Table 2) and her malig-
nant follow-up specimens. Upon retrospective review,Table 1 Ultrasound fine needle biopsy patient demographics
African American (%) Average age (yea
Benign 43/55 (78) 51.4
Atypical 5/6 (83) 60.8
Malignant 3/3 (100) 79.7
Total 51/64 (80) 53.6reduced CK5/6 and CK903 immunostains were helpful
for upgrading three of the CNBs from intraductal pa-
pilloma into malignancy (DCIS or invasive carcinoma,
Illustrated in Figure 1D – E).
Discussion
To the best of our knowledge, there have not been pub-
lished studies specifically examining the accuracy of CNB
for breast non-malignant papillary lesions in specific eth-
nic groups. However, clinical and biological differences are
known to exist between the ethnic groups. For example,
African-American women with breast cancer are reported
to be more likely to have advanced disease at diagnosis, es-
trogen receptor negative, a high S-phase fraction, higher
risk of recurrence and poorer prognosis than Caucasian
women [8]. Insulin-like growth factor II receptor expres-
sion is higher in breast tumor of African-American women
than those of any other ethnic group [9]. Compared to
Caucasian women, African American women carry more
risk factors for breast cancer: younger age at first live birth,
less and shorter breast feeding, higher BMI, less moderate
physical activity [10]. While alcohol consumption increase
breast cancer risk in Caucasian women, recent alcohol
consumption apparently does not affect breast cancer risk
in African American women, while early age drinking in
this ethnic group seems to decrease the risk [11]. Asso-
ciation between 5p12 genomic markers and breast
cancer susceptibility was identified in Caucasians and East-
Asians, but not in Africans or African-Americans [12]. Re-
sults in our study show a large percentage (25%) of benign
or atypical papillary lesions diagnosed on CNB will be
upgraded in the final excisional examination in a primarily
African-American patient population. Our upgraded rate
is slightly higher than the median percent of underestima-
tion (16.6%) based on a meta-analysis of 34 studies from
mixed ethnic groups [7]. While this is an interesting trend,
the small patient number of our study warrants further in-
vestigation of this question.
Pathological classification of breast papillary lesions on
CNB, especially on H & E preparation alone, can be
challenging. Classical intraductal papilloma shows obvi-
ous myoepithelial cells covering fibrovascular cores, a
polymorphic epithelial cells and normochromatic nuclei;
on the other hand, papillary DCIS has no or scant myoe-
pithelial cells, its neoplastic epithelial cells are mono-





Table 2 Patients with upgraded lesions on subsequent excision
Age Original core needle
biopsy diagnosis







1 42 y Papilloma Originally; Minimal CK5/6, CK903stains. Invasive Ca No Lumpectomy
2 74 y Papilloma Retrospectively; Minimal CK5/6, CK903 stains Invasive papillary Ca No Mastectomy
3 75 y Papilloma Originally; Focal weak CK5/6, CK903 stain. DCIS Focal weak CK5/6, CK903 stain Lumpectomy
4 76 y Papillomatosis Retrospectively; Minimal CK5/6, CK903 stains DCIS, microinvasive Minimal CK5/6, CK903 stains Lumpectomy
5 56 y Papilloma Retrospectively; Reduced CK5/6, CK903 stains DCIS Reduced CK5/6, CK903 stain Lumpectomy
6 54 y Papilloma w/atypia Originally; Reduced CK5/6, CK903 stains DCIS Reduced CK5/6, CK903 stains Lumpectomy




Figure 1 Core needle biopsy of an originally diagnosed atypical intraductal papilloma (1A, H & E, original magnification: × 100);
retrospective CK5/6 immunohistochemical analysis showed minimal positive staining (1B, original magnification × 100). Mastectomy
examination upgraded the lesion to invasive papillary carcinoma (1C, H & E, original magnification: × 100), and absence of CK5/6 stain (1D,
original magnification × 100), CK903 (1E, original magnification × 100), p63 (1F, original magnification × 100).
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Table 3 Difference between clinicopathological variables




Mean age (years) 47.7 ± 11.1 64.6 ± 13.7 0.017
Lesion size (mm) 16.8 ± 9.1 22.2 ± 12.2 N.S.
Distance from
nipple (cm)
3.2 ± 4.1 8.3 ± 4.6 N.S.
Microcalcification 4/14 1/4 N.S.
BI-RADS 4B: 7/11; 4A: 2/11; 2: 2/
11; not evaluated: 11
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loma with focal population of monotonous cells with the
cytological and architectural features of low grade ductal
neoplasia, scant or absent myoepithelial cells in these
foci, and the atypical epithelial cells usually show lack of
staining for high-molecular weight keratin and uniform
positivity for estrogen receptor. Over the years, many in-
vestigators have suggested immunohistochemical stains
on CNB enhance diagnostic accuracy [14-17]. In this
sense, it is interesting to note that in a meta-analysis of
published studies, a decreasing trend of underestimation
was obvious over time between CNB and surgical excision
[7]. Furthermore, a recent study from Toronto, Ontario
points out that correlation between CNB and excision
diagnoses for breast papillary lesions is significantly
greater for pathologists specialized in breast than for other
pathologists [18]. As part of current study, we performed
and re-evaluated immunostains (CK5/6 and CK903) on all
seven CNBs that were upgraded to intraductal papillary
carcinoma on subsequent specimens. While the discrep-
ancy on some cases was due to sampling, the diagnosis of
three core biopsies should be upgraded to malignant
according to current diagnostic criteria using immunohis-
tochemistry. Immunostains, as well as other molecular
investigative procedures [19], can be very helpful in bor-
derline cases. Another potential source of discrepancy be-
tween CNB and excision comes from the heterogeneous
nature of the papillary lesion even within a single lesion.
Different approaches have been proposed to evaluate le-
sions of great intrinsic variability, including extended bi-
opsy [20], powered biopsy system [21], and assessment
aided by automated intelligent system [22,23]. Application
and evaluation of theses novel approaches in breast CNB
may help to more accurately classify papillary lesions.
When and if possible, more advanced continued education
of breast pathology should be encouraged for all practicing
pathologists.
Several clinical and radiological variables, including pa-
tient’s age, lesion size, distance from nipple, BI-RADS cat-
egory, have been examined in relations to their predictive
value of pathological upgrading from CNB to excisionalbiopsy. Great efforts have been made, but conclusions
from different reports vary significantly [24-27]. In our co-
hort, the average age of these upgraded cases was 65 years,
compared to an average of 48 years among those patients
without upgrading. We also evaluated the relationship be-
tween upgrading and lesion size, distance from nipple,
microcalcification, and BI-RADS category, none of which
achieved statistical significance. Hence, in our study of pri-
marily African American population in an urban setting,
older age appeared to be an important factor in predicting
diagnostic upgrade to a more severe lesion.
Conclusions
In summary, our study has shown a trend of slightly
higher percentage (25%) of upgrading of breast papillary
lesions in our predominantly African-American urban
population compared to a meta-analysis of mixed ethnic
groups published in the literature. The use of immuno-
histochemistry can increase the diagnostic accuracy of
CNB. Early excision of all papillary breast lesions diag-
nosed by core needle biopsy may be justified in this pa-
tient population due to the relatively high chance of a
more severe lesion.
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